- Home
- GHI vs DMAC Comparison
GHI vs DMAC Comparison
Compare GHI & DMAC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
GHI
Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Current Price
Company Overview
Basic Information| Metric | GHI | DMAC |
|---|---|---|
| Founded | 1998 | 2000 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 161.5M | 441.6M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | GHI | DMAC |
|---|---|---|
| Price | $7.28 | $8.22 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 4 |
| Target Price | $13.00 | ★ $15.50 |
| AVG Volume (30 Days) | 170.8K | ★ 470.5K |
| Earning Date | 11-06-2025 | 11-12-2025 |
| Dividend Yield | ★ 20.53% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.17 | N/A |
| Revenue | ★ $26,247,399.00 | N/A |
| Revenue This Year | $201.02 | N/A |
| Revenue Next Year | $2.87 | N/A |
| P/E Ratio | $42.74 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $6.01 | $3.19 |
| 52 Week High | $13.29 | $10.42 |
Technical Indicators
Market Signals| Indicator | GHI | DMAC |
|---|---|---|
| Relative Strength Index (RSI) | 55.77 | 49.57 |
| Support Level | $6.99 | $8.16 |
| Resistance Level | $7.50 | $8.73 |
| Average True Range (ATR) | 0.32 | 0.61 |
| MACD | 0.13 | -0.13 |
| Stochastic Oscillator | 82.73 | 9.30 |
Price Performance
Historical ComparisonAbout GHI Greystone Housing Impact Investors LP Beneficial Unit Certificates representing assignments of limited partnership interests
Greystone Housing Impact Investors LP engaged in acquiring a portfolio of mortgage revenue bonds (MRBs) that are issued by state and local housing authorities to provide construction and/or permanent financing for affordable multifamily housing, seniors housing, and commercial properties. It has four reportable segments, namely Affordable Multifamily MRB Investments, Seniors and Skilled Nursing MRB Investments, MF Properties, and Market-Rate Joint Venture Investments. It generates the majority of its revenue from the Affordable Multifamily MRB Investments segment.
About DMAC DiaMedica Therapeutics Inc.
DiaMedica Therapeutics Inc is a clinical-stage biopharmaceutical company. The company is engaged in developing treatment for ischemic diseases with two main clinical programs focused on acute ischemic stroke (AIS) and preeclampsia (PE). Its main product candidate DM199 (rinvecalinase alfa) is a recombinant form of human tissue kallikrein-1, which is a synthetic version of the naturally occurring protease enzyme kallikrein-1 and a rhKLK1 undergoing clinical development studies in both AIS and PE. The other product candidate in the company's pipeline is DM300, its patented recombinant human ulinastatin, a broad-spectrum serine protease inhibitor, being developed as a potential therapy for severe acute pancreatitis.